SCHEMBL29173658

SCHEMBL29173658

CNc1nc(Nc2ccnc(C)c2)c(C(=O)OC)nc1-c1cncc2c1ncn2C

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ BUB1 O43683 1/20 0.34
▸ HDAC3 O15379 1/20 0.32
▸ HDAC1 Q13547 1/20 0.32
▸ HDAC2 Q92769 1/20 0.32
▸ HDAC6 Q9UBN7 1/20 0.32
▸ GRM5 P41594 3/20 0.32
▸ TGFBR1 P36897 1/20 0.31
▸ TTK P33981 1/20 0.31
▸ PIK3C3 Q8NEB9 1/20 0.30
▸ ABL1 P00519 1/20 0.30
▸ BCR P11274 1/20 0.30
▸ SRC P12931 1/20 0.30
▸ SYK P43405 1/20 0.30
▸ PSEN1 P49768 1/20 0.30
▸ PSEN2 P49810 1/20 0.30
▸ APH1B Q8WW43 1/20 0.30
▸ NCSTN Q92542 1/20 0.30
▸ APH1A Q96BI3 1/20 0.30
▸ PSENEN Q9NZ42 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30205968 0.91 HPGD (0.32) —
SCHEMBL29173474 0.91 HPGD (0.32) —
SCHEMBL29173433 0.91 TGFBR1 (0.33) BUB1TGFBR1TTKPIK3C3ABL1
SCHEMBL30206243 0.91 TGFBR1 (0.33) BUB1TGFBR1TTKPIK3C3ABL1
SCHEMBL24944974 0.91 ALK (0.34) HDAC3HDAC1HDAC2HDAC6GRM5
Formic Acid SCHEMBL30205522 0.88 AURKA (0.33) HDAC3HDAC1HDAC2HDAC6GRM5
Formic Acid SCHEMBL29173295 0.88 AURKA (0.33) HDAC3HDAC1HDAC2HDAC6GRM5
SCHEMBL30206107 0.87 CYP1A2 (0.35) TTKSRC
SCHEMBL29173378 0.87 CYP1A2 (0.35) TTKSRC
SCHEMBL24943808 0.83 EML4 (0.33) TGFBR1SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373817-B1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2025-05-21 — — EP disclosed
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2024-11-14 — — US disclosed
EP-4373817-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER Astrazeneca AB (SE) 2024-05-29 — — EP disclosed
CN-117693503-A Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer 阿斯利康(瑞典)有限公司 2024-03-12 — — CN disclosed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER PDXK, PGK1, PGK2 BUB1 313/4885HDAC3 328/4885HDAC1 259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback